CTMX
CytomX Therapeutics, Inc.
stockNASDAQ
cytomx is an oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its probody technology platform. the company uses the platform to create development-stage proprietary cancer immunotherapies against clinically-validated targets, as well as to develop first-in-class investigational cancer therapeutics against novel targets. cytomx believes that its probody platform has the potential to improve the combined efficacy and safety profile of monoclonal antibody modalities, including cancer immunotherapies, antibody drug conjugates and t-cell-recruiting bispecific antibodies. probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. investigational probody therapeutics are being developed that address clinically-validated cancer targets in immuno-oncology, such as pd-l1 against which o
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 2.69 | 2026-09-28 | -5.02% | -3.601 |
| 1M | 3.71 | 2026-09-04 | -31.13% | 1.786 |
| 3M | 3.81 | 2026-07-06 | -32.94% | 1.139 |
| 6M | 4.40 | 2026-04-06 | -41.93% | 0.919 |
| 1Y | 3.28 | 2025-10-06 | -22.10% | 1.770 |
| 2Y | 1.15 | 2024-10-04 | +122.17% | — |
| 5Y | 4.89 | 2021-10-05 | -47.75% | 1.356 |
CytomX Therapeutics, Inc. (NASDAQ:CTMX) stock price today is $2.56, and today's volume is 2,624,133. CTMX is down 2.852% today. The 30 day average volume is 3.98M. CTMX market cap is $556.73M with 217.90M shares outstanding.